Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 5,241 matching trials from the live ClinicalTrials.gov search.
Terminated Phase 1 Interventional

BAY1238097, First in Man

NCT02369029
Conditions
Neoplasms
Interventions
BAY 1238097
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
MGMT-Methylated Glioblastoma, Glioblastoma (GBM), Newly Diagnosed Glioblastoma Multiforme
Interventions
Granulocyte Colony Stimulating Factor (G-CSF), Radiation Therapy + Temozolomide
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Stage IIIC Melanoma, Stage IV Melanoma
Interventions
Denileukin diftitox
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Conditions
Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PS-341, Doxil, Velcade
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Withdrawn No phase listed Observational

Yervoy Pregnancy Surveillance Study

NCT02854488
Conditions
Melanoma
Interventions
Yervoy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma
Interventions
Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 22 more
Conditions
Malignant Glioma
Interventions
MK-2206
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Terminated Phase 2 Interventional Results available

Neoadjuvant Immunotherapy in Brain Metastases

NCT04434560
Conditions
Brain Metastases, Adult
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Sarah Sammons, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Diffuse Intrinsic Pontine Glioma, PNET, Ependymoma, Germinoma, Medulloblastoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 21 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Melanoma
Interventions
Tetanus Diptheria Vaccine, Polio Boost Immunization
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
etoposide, ifosfamide, intensity-modulated radiation therapy, topotecan hydrochloride, busulfan, melphalan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, autologous bone marrow transplantation
Drug · Radiation · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Duarte, California
Conditions
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation
Interventions
Ulixertinib (BVD-523)
Drug
Lead sponsor
xCures
Industry
Eligibility
12 Years and older
U.S. locations
26
States / cities
Mobile, Alabama • Arroyo Grande, California • Newport Beach, California + 19 more
Conditions
Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Interventions
CB-10-01 (Transgenic Lymphocyte Immunization)
Biological
Lead sponsor
Cosmo Bioscience
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 2 more
Conditions
Glioblastomas, Sarcoma, Astrocytoma, Brain Cancer, Leukemia
Interventions
Enhanced Mindfulness Intervention, Psychoeducation
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 24 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
Interventions
Pharmacological Study, Romidepsin
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
11
States / cities
Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more
Conditions
Glioma
Interventions
5-Aminolevuline Acid
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Cutaneous Melanoma
Interventions
Not listed
Lead sponsor
Castle Biosciences Incorporated
Industry
Eligibility
16 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Santa Rosa, California • Frederick, Maryland • Las Vegas, Nevada + 1 more
Conditions
Head and Neck Cancer
Interventions
paclitaxel, semaxanib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
sargramostim
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
87
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 54 more
Conditions
Neuroblastoma
Interventions
UltratraceTM Iobenguane I 131 Imaging, UltratraceTM Iobenguane I 131 Therapy
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 5 more
Conditions
High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma
Interventions
Tumor Lysate Vaccine, Imiquimod
Biological · Drug
Lead sponsor
Frank Lieberman
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
Beta-Glucan
Dietary Supplement
Lead sponsor
Kelly McMasters
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Brain and Central Nervous System Tumors
Interventions
lymphokine-activated killer cells, polifeprosan 20 with carmustine implant
Biological · Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Newport Beach, California